TY  - GEN
AU  - Varghese,Abraham M
AU  - Howard,Dena R
AU  - Pocock,Christopher
AU  - Rawstron,Andy C
AU  - Follows,George
AU  - McCarthy,Helen
AU  - Dearden,Claire
AU  - Fegan,Christopher
AU  - Milligan,Donald
AU  - Smith,Alexandra F
AU  - Gregory,Walter
AU  - Hillmen,Peter
TI  - Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation
SN  - 1365-2141
PY  - 2017///0608
KW  - Adult
KW  - Aged
KW  - Alemtuzumab
KW  - Antibodies, Monoclonal, Humanized
KW  - adverse effects
KW  - Bone Marrow Examination
KW  - Consolidation Chemotherapy
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm, Residual
KW  - Recurrence
KW  - Survival Rate
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/bjh.14342
ER  -